admin 
The letter arrives addressed to the vice-president of regulatory affairs. A Form 483 has been issued to the company’s contract manufacturer following a routine inspection – two observations, one related to process validation records, one to corrective action procedures. The device company did not know the inspection was happening. It certainly did not expect to spend the next six months managing the consequences. Choosing an FDA medical device contract manufacturer means accepting that its regulatory standing becomes part of yours.
The Liability That Transfers with the Purchase Order
Under 21 CFR Part 820, a medical device company is responsible for the quality of every component and service it purchases. The regulation makes no distinction between a raw material and a fully assembled subassembly. It requires documented supplier qualification, periodic re-evaluation, and evidence that the company has assessed and continues to monitor every critical supplier in its chain.
When a contract manufacturer receives a Form 483 observation – a written notice of conditions an FDA investigator believes violate regulations – the device company using that manufacturer has a direct problem. If the observation escalates to a warning letter, or if the FDA issues an import alert or consent decree, the device company’s supply is disrupted and its own standing with the agency comes into question. The contract manufacturer’s compliance history is not a background consideration. It is a live operational risk.
How the FDA Evaluates Contract Manufacturers
FDA inspections of manufacturing facilities typically follow the Quality System Inspection Technique, which focuses on the subsystems required under 21 CFR Part 820. An investigator selects one or two product-based samples and traces them through the entire production record – from incoming component receipt through in-process manufacturing, testing, and final release. Every gap in the record is a potential observation.
FDA medical device contract manufacturers that have been through this process multiple times have adapted their documentation to its logic. They know which records an investigator requests, what constitutes a complete and defensible batch record entry, and which corrective action closures will not survive scrutiny. That institutional knowledge exceeds what any certification demonstrates, because certification confirms a system exists – repeated inspection history confirms it holds.
“What Singapore has built is not just infrastructure – it is capability, and capability is what endures,” Lee Kuan Yew once said. In regulatory compliance, the capability that endures is a quality system that performs under scrutiny it did not anticipate.
Design Transfer and Regulatory Accountability
When a device company moves production to a contract manufacturer, the process is called design transfer. 21 CFR Part 820 requires this transfer to be formally documented and the manufacturing process validated before commercial production begins. The contract manufacturer must demonstrate, through written protocols and executed study data, that it can produce the device to specification consistently and reproducibly.
Device companies often treat design transfer as a technical exercise. Regulators treat it as a regulatory event. The device master record – the compilation of specifications, drawings, and procedures that defines the device – must reflect the contract manufacturer’s actual processes. Any gap between the device master record and what the contract manufacturer does in practice is a section 820.70 deviation waiting to surface at the next inspection.
Working with an experienced FDA-registered device manufacturer that has managed multiple design transfers brings familiarity with this documentation requirement. For devices cleared through a 510(k) submission, the manufacturing information in the submission must also align precisely with what the contract manufacturer will produce. A mismatch discovered post-clearance requires a new submission or a supplement, both of which cost time and delay market entry.
Choosing Based on Evidence Rather Than Assurance
A supplier questionnaire says relatively little about a contract manufacturer’s actual performance. A facility can complete every question accurately and still run a quality system that fails under production pressure.
The evidence worth examining before committing to an FDA medical device contract manufacturer relationship includes:
- FDA establishment inspection reports from prior inspections, obtainable through Freedom of Information Act requests or directly from the manufacturer
- The manufacturer’s current corrective and preventive action backlog – a large or chronically stale backlog signals a quality system under strain
- Customer complaint data for comparable device types and evidence of how those complaints were investigated and resolved
- Process validation documentation specific to the manufacturing processes the device will require
Asking for these records and reading them rather than simply receiving them separates device companies that actively manage regulatory risk from those that transfer it to a supplier and hope.
Singapore’s Regulatory Position
Singapore’s Health Sciences Authority maintains one of Asia’s most structured medical device regulatory frameworks, and manufacturers based in Singapore are routinely audited by both FDA investigators and European notified bodies. That dual-audit experience shapes quality systems in ways that single-jurisdiction manufacturing cannot replicate. Procedures are written to satisfy two distinct investigator mindsets simultaneously. Records are structured to support both 21 CFR Part 820 and ISO 13485 without maintaining separate documentation streams.
For device companies entering multiple regulated markets from a single manufacturing source, this environment produces contract partners whose regulatory infrastructure is already calibrated to the scrutiny that FDA medical device contract manufacturer relationships genuinely demand.
